CAR-T Cell Therapy for Lymphoma That Starts in the Brain: A Review of Past Studies
Original title: Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
It has been tried in small groups of people, but it is not yet proven or standard for this cancer.
The short version
Researchers looked at many small studies of a cell therapy for a rare brain cancer and found it often helped for a while.
What was studied. Researchers gathered past studies on CAR-T therapy for lymphoma that starts in the brain or spinal cord. CAR-T uses a person's own immune cells, changed in a lab to attack cancer. They pooled 15 studies with 194 patients.
What they found. The cancer shrank in 68% of patients, and it went away on scans in 57%. About 79% were alive at 6 months and 60% at 12 months. Side effects were common, like an immune reaction in 72% and brain side effects in 46%, and 5% died from the treatment.
What this means, and what it doesn't
What it could mean: This therapy may help some people with this cancer, at least for a while. The good results often did not last. Side effects can be serious, so it needs careful care.
What it doesn't mean: This is not a cure. It is a review of small past studies, not a new trial. The studies were mixed, and the good results often faded over time. It is not yet standard care for this cancer, so talk with your doctor.
Source: PubMed, September 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.